Skip to main content


Fig. 5 | BMC Medical Genomics

Fig. 5

From: Sequencing and curation strategies for identifying candidate glioblastoma treatments

Fig. 5

WGS vs focused NGS panel comparison. Number of calls made based on WGS versus calls made by focused NGS panel testing per patient. Blue indicates variant calls made uniquely by NY-GGC, green indicates variant calls made uniquely by panel testing, yellow indicates common calls made, purple indicates germline variants called as tumor variants by panel testing; *panel testing done on subsequent sample, **panel testing done on prior sample, ^partial report of panel testing available, Panel 1 = Memorial Sloan Kettering Cancer Center IMPACT Panel, Panel 2 = FoundationOne, Panel 3 = NYU Next Generation Tumor 50 Panel, Panel 4 = Weill Cornell Institute of Precision Medicine’s whole exome sequencing assay, Panel 5 = University of California San Francisco’s 500 Cancer Gene Panel, Panel 6 = Caris Molecular Intelligence’s profile which includes next generation sequencing analysis of 44 genes as well as other assays such as immunohistochemistry

Back to article page